

NIHR Manchester Biomedical Research Centre (MBRC) Pump Prime Funding

TERMS AND CONDITIONS

Acknowledgements

A statement should be incorporated within the acknowledgements of publications and other disseminations of research results following studies undertaken at Manchester BRC.

Scenario 1: Use the BRC funded statement if: Your research is fully or majority funded by the BRC

“This study/research is funded by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.”

Please also acknowledge any other NIHR support the research may have received.

Scenario 2: Instances where the research was funded by another funder but delivered through* the BRC Statement (including funder and disclaimer)

“[Research funder statement] This study has been delivered through the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308). The views expressed are those of the author(s) and not necessarily those of the [name of the research funder], the NIHR or the Department of Health and Social Care.”

*We define ‘delivered through’ as a project that is supported by Manchester BRC workforce, resources and/or infrastructure to meet the outputs as published, for example BRC-funded or affiliated project managers, use of trial delivery teams, technology platforms or support services, a PhD student supervised by a BRC Theme/programme Lead.

Please also acknowledge any other NIHR support the research may have received, for example, through a research programme award.

Scenario 3: Minimum statement to be used in instances where there are funder details and/or word count restrictions AND the research was funded by another funder but delivered through the BRC

Acknowledgement only (for use within a broader set of acknowledgements and/or disclaimers)

“The research was carried out at the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308).”

Scenario 4: Instances where the researcher, but not the research study or project, is funded or supported by the BRC

“[Researcher name] is funded/supported [delete as appropriate] by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308).”

Animals

Manchester BRC does not fund animal research.

Award Letter

The award letter will act as a contract for the delivery of the project as detailed in the approved application. You must inform Manchester BRC, in writing if there is deviation from the original scope of the project. The issuing award letter will detail awardee details, award amount, name of project and dates for deliverables.

Employment

Applications can be led by BRC and Non-BRC affiliated individuals. In the case of a lead applicant not having a BRC affiliation, it would be expected that some co-applicants from the BRC would be included.

The lead applicant must hold an appropriate contract with the BRC partner organisation where the project activity will take place and should exceed the duration of the proposed project.

Partner organisations are:

- The University of Manchester
- Manchester University NHS Foundation Trust
- The Christie NHS Foundation Trust
- Greater Manchester Mental Health NHS Foundation Trust
- Northern Care Alliance NHS Foundation Trust
- Blackpool Teaching Hospitals NHS Foundation Trust
- Lancashire Teaching Hospitals NHS Foundation Trust

If the recipient of the award is an early career researcher it is expected the senior co-I will oversee the project undertaken with the award and both the awardee and the senior co-I will be responsible for the potential follow-on project and reporting.

Inclusive Research

Inclusive translational research takes deliberate action to meet the health research needs of different people, to address barriers to inclusion and to promote environments where everyone feels included, respected and valued

Patient and public involvement and engagement (PPIE), inclusive research methods (IRM) and workforce equality, diversity and inclusion (EDI), must be acknowledged and included in each funding call. Applicants are expected to provide detail on how PPIE, IRM and EDI principles have been considered and applied throughout the project, if applicable.

All funding calls are subject to EDI monitoring questions which will help inform us of who is applying vs those being awarded. This data will be pseudo anonymised and supplied to NIHR, on request.

By accepting this award you agree to being contacted in the future by Manchester BRC for data gathering initiatives, surrounding equality, diversity and inclusion measures which could inform in equality monitoring.

Equipment

Equipment may be bought up to the cost of £5,000 per item. Consider leasing equipment above this price threshold.

Expenditure

The budget may be used to support the following:

- Directly incurred staff costs
- Materials and consumables – these should be project specific and not general costs
- Equipment/facilities access
- Equipment purchases (capped at £5,000 per item and must be justified against the duration of the project)
- Workshops
- Other engagement, knowledge exchange, training and culture change activities can also be supported.

All funds must be spent by the agreed project end date as stated in your award letter. Clearance of invoices will be permitted for 3 months after the project end date.

On occasion, cost extensions may be considered, for extenuating circumstances and must be submitted, in writing for the review and approval from the Strategic Executive Board.

Underspend cannot be carried over to the next financial year.

Intellectual property

Examples of IP that may be developed from clinical-academic research include: training manuals or programmes, e-learning modules, software, clinical guidelines, films, audio recordings, inventions, new or improved designs, images, medical devices, equipment, new uses for existing drugs, biomarkers and diagnostic tests, and new treatments or interventions.

Any IP generated from this project must be used for the benefit of patients and healthcare.

Any IP must comply with NIHR terms and conditions [\[click here for NIHR IP T&C\]](#)

Prior to commercialisation, you must seek consent from NIHR through their IP unit. Please contact our Innovations and Partnership team for more information: [\[Colette.Inkson@mft.nhs.uk\]](mailto:Colette.Inkson@mft.nhs.uk)

Impact

Manchester BRC may informally contact the awardee(s), up to five year's post-award, to record the progress made and impact delivered. As a condition of funding an impact plan should be developed, and Manchester BRC will offer support on this for successful applicants.

Liability

Manchester BRC accepts no liability from the research funded by this award, financial or otherwise.

Monitoring

You must inform us in writing if there is a significant change in the project which will lead to a delay of its progress and/or outcomes.

The BRC may request information on the project at any time for monitoring purposes.

Responsibilities for the Awardee

The award holder must ensure that all ethical and regulatory requirements associated with the project are fulfilled, including from any third party and collaborative parties supporting the project.

The award holder must ensure all project costs (including but not limited to staff time, consumables, sponsorship, third party providers, site costs) have either been included within the application or alternative sources of funding identified.

The award must be spent solely on the objectives and purpose as detailed in the approved application.

By accepting this funding award, you are confirming that you have not received any competitive funding from any other source for this same research project, as detailed in the approved application.

Reporting

A formal interim report is expected half-way through the project, outlining project progress against the milestones set out in the application. If the project duration is <6 months, only a final report is required. A final report, outlining outcomes is expected within 1 month of the project end date.

We reserve the right to request an interim report on project progress at any point of the funding period.

The BRC may also request updates for submission to the NIHR or for use for internal reporting and governance purposes for up to 5 years post award.

Payment

Funding for year 1 of the project will be issued within 4 weeks of the dated award letter. Funding from year 1 must be spent by 31st March 2026.

Funding for year 2 of the project (if applicable) will be issued within 4 weeks from the start of the next financial year, 1st April 2026. Funding from year 2 must be spent by 31st March 2027.